Mineralys Therapeutics, Inc.
Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.
MLYS | NDAQ
Overview
Corporate Details
- ISIN(s):
- US6031701013
- LEI:
- Country:
- United States of America
- Address:
- 150 N. RADNOR CHESTER ROAD, 19087 RADNOR
- Website:
- https://mineralystx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted treatments for diseases driven by abnormally elevated aldosterone. The company's primary objective is to improve outcomes for patients managing hypertension, chronic kidney disease (CKD), and other related conditions. Its lead therapeutic candidate is an aldosterone synthase inhibitor, a novel approach designed to control dysregulated aldosterone, a key driver of these diseases. Mineralys aims to deliver a best-in-class therapy for millions of people affected by uncontrolled or resistant hypertension.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Mineralys Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Mineralys Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Mineralys Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
